Health
Guinea-Bissau reports first suspected mpox cases as global health officials monitor spread
Unicef reports 46 suspected cases in the country, half of them in children under 15, amid broader global efforts to contain the virus.
The short version
- Guinea-Bissau has reported its first suspected cases of mpox, with half of the 46 reported cases occurring in children under the age of 15.
- Health experts emphasize that early detection, contact tracing, and supportive clinical care remain critical alongside vaccine deployment to contain outbreaks.
- A new global vaccine stockpile is scheduled to launch within weeks to improve equitable distribution and access in lower-income regions.
Key facts
- Guinea-Bissau reported 46 suspected mpox cases, marking the country's first recorded cases of the virus.[The Guardian]
- According to Unicef, 23 of the suspected cases in Guinea-Bissau are children under age 15, with most under four years old.[The Guardian]
- Global reporting indicates nearly 190,000 lab-confirmed mpox cases across 145 countries since 2022.[The Guardian]
- Clinical trial results in the Democratic Republic of the Congo showed the antiviral tecovirimat performed no better than a placebo for clade I mpox patients, though supportive care significantly reduced mortality.[The Guardian]
- A global vaccine stockpile is expected to launch in the coming weeks to facilitate faster delivery to low-income nations.[The Guardian]
What remains uncertain
- Health officials note that data showing a high proportion of pediatric cases may reflect healthcare-seeking bias by families rather than true epidemiological prevalence in children.[The Guardian]
- It remains uncertain whether the antiviral tecovirimat offers clinical benefits to specific sub-populations, such as immunocompromised patients living with HIV.[The Guardian]
Sources
- Mpox is back – and in new countries. How this outbreak can be containedThe Guardian - Science